Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
New inhalers would have near-zero Global Warming Potential propellant
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
Subscribe To Our Newsletter & Stay Updated
